THRX 14.40 Theravance $THRX Hit a 52 week low of 1
Post# of 42
Posted On: 11/06/2014 11:31:36 PM
THRX 14.40 Theravance $THRX Hit a 52 week low of 14.13 Closing the day 11/06/14 at 14.40 -0.19 -1.30% With a day low of 14.13 and a total volume of 1,719,719.
THRX Recent Posts: http://investorshangout.com/Theravance-THRX-55637/
THRX Theravance Recent Headline News
5 Stocks With Big Insider Buying in November: NuStar, Huntsman and More
at The Street - Thu Nov 06, 11:45AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
SCCO: 29.00 (-0.01), WRLD: 73.94 (-0.63), NS: 60.10 (-1.38), THRX: 14.40 (-0.19), HUN: 24.94 (+0.57)
Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 05, 3:08PM CST
Theravance, Inc. (NASDAQ: THRX) today announced Michael W. Aguiar, President and Chief Executive Officer of Theravance, will be presenting at two upcoming investor conferences in November.
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19)
Real Money's Brian Sozzi: A Primer on Investing in Retail Stocks
at The Street - Wed Nov 05, 11:38AM CST
Some thoughts on the outlook of the retail sector and what to look for before you invest.
COH: 33.46 (+0.44), TJX: 64.56 (+0.84), NKE: 94.60 (-0.08), TGT: 61.89 (+0.77), WMT: 77.81 (+0.11), HBI: 109.56 (+2.30), THRX: 14.40 (-0.19), KORS: 72.31 (-0.09), GPS: 37.90 (+0.65), RL: 171.39 (+6.61), LULU: 42.78 (+1.49)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.12 (+0.34), TBPH: 17.44 (-0.25), GSK: 44.75 (-0.39), THRX: 14.40 (-0.19)
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.26 (-0.31), AMAG: 34.12 (+0.34), THRX: 14.40 (-0.19)
Theravance misses Street 3Q forecasts
Automated Insights - Fri Oct 31, 4:04AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Theravance Inc. (THRX) on Friday reported a third-quarter loss of $21.3 million.
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19)
Theravance Has Returned 40.7% Since SmarTrend Recommendation (THRX)
Comtex SmarTrend(R) - Thu Oct 30, 4:38PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 40.69% as of today's recent price of $16.21.
THRX: 14.40 (-0.19)
Theravance Reports Third Quarter 2014 Financial Results
Marketwired - Thu Oct 30, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19), TBPH: 17.44 (-0.25)
Theravance to Report Third Quarter 2014 Financial Results on October 30, 2014
Marketwired - Thu Oct 23, 3:07PM CDT
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended September 30, 2014 after market close on Thursday, October 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19)
Nasdaq stocks posting largest percentage decreases
AP - Thu Oct 23, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
EMKR: 5.18 (+0.02), VBFC: 18.65 (-1.32), AIRM: 46.64 (+0.32), JAKK: 6.54 (+0.31), ASPS: 70.16 (-0.79), THRXV: 28.00 (+7.07), ANGI: 6.45 (-0.12), BDBD: 8.59 (+0.08), LAKE: 12.87 (-0.88), THRX: 14.40 (-0.19), SUSQ: 9.78 (+0.06), CTXS: 65.99 (+1.58), CREE: 32.49 (-0.14)
36.6% Return Seen to Date on SmarTrend Theravance Call (THRX)
Comtex SmarTrend(R) - Thu Oct 23, 10:59AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 36.59% as of today's recent price of $17.33.
THRX: 14.40 (-0.19)
After Yesterday's Decline of 8.91%, Theravance Offers Investors Better Value
Comtex SmarTrend(R) - Wed Oct 22, 5:42PM CDT
Theravance (NASDAQ:THRX) traded in a range yesterday that spanned from a low of $16.46 to a high of $18.43. Yesterday, the shares fell 8.9%, which took the trading range below the 3-day low of $16.63 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
THRX: 14.40 (-0.19)
Amgen Gains as Third Point Suggests Split - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 12:50PM CDT
Amgen Inc. (AMGN) jumped 4.79% as Third Point, a hedge fund firm, increased its stake in the company.
ABT: 43.69 (+0.03), LGND: 54.91 (-0.38), AMGN: 160.35 (+1.41), THRX: 14.40 (-0.19)
Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium
Marketwired - Fri Oct 17, 4:00AM CDT
Theravance, Inc. (NASDAQ: THRX) -- Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro(R) Ellipta(R) (umeclidinium /vilanterol, 'UMEC/VI'), the combination long-acting muscarinic antagonist (LAMA) / long-acting beta2-adrenergic agonist (LABA), with the LAMA tiotropium, administered in the HandiHaler(R) inhaler, in patients with chronic obstructive pulmonary disease (COPD).(1)
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19)
Downtrend Call Working As Theravance Stock Falls 37.8% (THRX)
Comtex SmarTrend(R) - Thu Oct 16, 9:38AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 37.80% as of today's recent price of $17.00.
THRX: 14.40 (-0.19)
4 Stocks Rising on Unusual Volume
at The Street - Thu Oct 16, 8:16AM CDT
Keep these stocks rising on unusual volume on your trading radar.
NOG: 10.71 (+0.20), BBEP: 16.70 (-0.55), THRX: 14.40 (-0.19), NLS: 14.73 (-0.25)
3 High-Yield Dividend Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Tue Oct 14, 7:20AM CDT
Source: TaxCredits.net via Flickr . Last week may have been a rough one for some investors, but it could be the perfect time to pick up a quality dividend stock. Dividends not only put extra income in your pocket, but they can be the sign of a...
ARCC: 16.13 (-0.01), AINV: 8.15 (unch), THRX: 14.40 (-0.19), GSK: 44.75 (-0.39), NVS: 92.03 (-0.60)
Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer
Marketwired - Thu Oct 09, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) today announced the appointment of Eric d'Esparbes as Senior Vice President and Chief Financial Officer. Mr. d'Esparbes will report directly to Michael W. Aguiar, Chief Executive Officer, and be responsible for overseeing financial and IT operations of the company.
THRXV: 28.00 (+7.07), PEG: 40.72 (-1.25), THRX: 14.40 (-0.19)
THRX Recent Posts: http://investorshangout.com/Theravance-THRX-55637/
THRX Theravance Recent Headline News
5 Stocks With Big Insider Buying in November: NuStar, Huntsman and More
at The Street - Thu Nov 06, 11:45AM CST
Insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
SCCO: 29.00 (-0.01), WRLD: 73.94 (-0.63), NS: 60.10 (-1.38), THRX: 14.40 (-0.19), HUN: 24.94 (+0.57)
Theravance to Present at Two Upcoming Investor Conferences in November
Marketwired - Wed Nov 05, 3:08PM CST
Theravance, Inc. (NASDAQ: THRX) today announced Michael W. Aguiar, President and Chief Executive Officer of Theravance, will be presenting at two upcoming investor conferences in November.
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19)
Real Money's Brian Sozzi: A Primer on Investing in Retail Stocks
at The Street - Wed Nov 05, 11:38AM CST
Some thoughts on the outlook of the retail sector and what to look for before you invest.
COH: 33.46 (+0.44), TJX: 64.56 (+0.84), NKE: 94.60 (-0.08), TGT: 61.89 (+0.77), WMT: 77.81 (+0.11), HBI: 109.56 (+2.30), THRX: 14.40 (-0.19), KORS: 72.31 (-0.09), GPS: 37.90 (+0.65), RL: 171.39 (+6.61), LULU: 42.78 (+1.49)
Theravance (THRX) Falls on Wider-than-Expected Loss in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:10AM CST
Theravance reported third-quarter 2014 loss of 19 cents per share.
AMAG: 34.12 (+0.34), TBPH: 17.44 (-0.25), GSK: 44.75 (-0.39), THRX: 14.40 (-0.19)
Bayer Q3 Earnings Grow Y/Y on New Product Sales, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:00AM CST
Bayer's (BAYRY) earnings during the third quarter of 2014 came in at roughly $1.79 per share.
MRK: 59.26 (-0.31), AMAG: 34.12 (+0.34), THRX: 14.40 (-0.19)
Theravance misses Street 3Q forecasts
Automated Insights - Fri Oct 31, 4:04AM CDT
SOUTH SAN FRANCISCO, Calif. (AP) _ Theravance Inc. (THRX) on Friday reported a third-quarter loss of $21.3 million.
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19)
Theravance Has Returned 40.7% Since SmarTrend Recommendation (THRX)
Comtex SmarTrend(R) - Thu Oct 30, 4:38PM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 40.69% as of today's recent price of $16.21.
THRX: 14.40 (-0.19)
Theravance Reports Third Quarter 2014 Financial Results
Marketwired - Thu Oct 30, 3:06PM CDT
Theravance, Inc. (NASDAQ: THRX) today reported financial results for the quarter ended September 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on December 23, 2014 to stockholders of record as of the close of business on November 25, 2014. Royalties received on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) were $4.0 million. Net loss for the third quarter of 2014 was $21.3 million or $0.19 per diluted share. Cash, cash equivalents, marketable securities and current restricted cash totaled $316.5 million as of September 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19), TBPH: 17.44 (-0.25)
Theravance to Report Third Quarter 2014 Financial Results on October 30, 2014
Marketwired - Thu Oct 23, 3:07PM CDT
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the period ended September 30, 2014 after market close on Thursday, October 30, 2014.
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19)
Nasdaq stocks posting largest percentage decreases
AP - Thu Oct 23, 12:52PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
EMKR: 5.18 (+0.02), VBFC: 18.65 (-1.32), AIRM: 46.64 (+0.32), JAKK: 6.54 (+0.31), ASPS: 70.16 (-0.79), THRXV: 28.00 (+7.07), ANGI: 6.45 (-0.12), BDBD: 8.59 (+0.08), LAKE: 12.87 (-0.88), THRX: 14.40 (-0.19), SUSQ: 9.78 (+0.06), CTXS: 65.99 (+1.58), CREE: 32.49 (-0.14)
36.6% Return Seen to Date on SmarTrend Theravance Call (THRX)
Comtex SmarTrend(R) - Thu Oct 23, 10:59AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 36.59% as of today's recent price of $17.33.
THRX: 14.40 (-0.19)
After Yesterday's Decline of 8.91%, Theravance Offers Investors Better Value
Comtex SmarTrend(R) - Wed Oct 22, 5:42PM CDT
Theravance (NASDAQ:THRX) traded in a range yesterday that spanned from a low of $16.46 to a high of $18.43. Yesterday, the shares fell 8.9%, which took the trading range below the 3-day low of $16.63 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
THRX: 14.40 (-0.19)
Amgen Gains as Third Point Suggests Split - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 12:50PM CDT
Amgen Inc. (AMGN) jumped 4.79% as Third Point, a hedge fund firm, increased its stake in the company.
ABT: 43.69 (+0.03), LGND: 54.91 (-0.38), AMGN: 160.35 (+1.41), THRX: 14.40 (-0.19)
Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium
Marketwired - Fri Oct 17, 4:00AM CDT
Theravance, Inc. (NASDAQ: THRX) -- Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro(R) Ellipta(R) (umeclidinium /vilanterol, 'UMEC/VI'), the combination long-acting muscarinic antagonist (LAMA) / long-acting beta2-adrenergic agonist (LABA), with the LAMA tiotropium, administered in the HandiHaler(R) inhaler, in patients with chronic obstructive pulmonary disease (COPD).(1)
THRXV: 28.00 (+7.07), THRX: 14.40 (-0.19)
Downtrend Call Working As Theravance Stock Falls 37.8% (THRX)
Comtex SmarTrend(R) - Thu Oct 16, 9:38AM CDT
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 3 months, Theravance has returned 37.80% as of today's recent price of $17.00.
THRX: 14.40 (-0.19)
4 Stocks Rising on Unusual Volume
at The Street - Thu Oct 16, 8:16AM CDT
Keep these stocks rising on unusual volume on your trading radar.
NOG: 10.71 (+0.20), BBEP: 16.70 (-0.55), THRX: 14.40 (-0.19), NLS: 14.73 (-0.25)
3 High-Yield Dividend Stocks Near 52-Week Lows Worth Buying
Motley Fool Staff - Motley Fool - Tue Oct 14, 7:20AM CDT
Source: TaxCredits.net via Flickr . Last week may have been a rough one for some investors, but it could be the perfect time to pick up a quality dividend stock. Dividends not only put extra income in your pocket, but they can be the sign of a...
ARCC: 16.13 (-0.01), AINV: 8.15 (unch), THRX: 14.40 (-0.19), GSK: 44.75 (-0.39), NVS: 92.03 (-0.60)
Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer
Marketwired - Thu Oct 09, 3:05PM CDT
Theravance, Inc. (NASDAQ: THRX) today announced the appointment of Eric d'Esparbes as Senior Vice President and Chief Financial Officer. Mr. d'Esparbes will report directly to Michael W. Aguiar, Chief Executive Officer, and be responsible for overseeing financial and IT operations of the company.
THRXV: 28.00 (+7.07), PEG: 40.72 (-1.25), THRX: 14.40 (-0.19)
(0)
(0)Innoviva, Inc. (INVA) Stock Research Links
Scroll down for more posts ▼